Literature DB >> 25957554

Experimental therapies in the neuronal ceroid lipofuscinoses.

Nicole J Neverman1, Hannah L Best1, Sandra L Hofmann2, Stephanie M Hughes3.   

Abstract

The neuronal ceroid lipofuscinoses represent a group of severe childhood lysosomal storage diseases. With at least 13 identified variants they are the most common cause of inherited neurodegeneration in children. These diseases share common pathological characteristics including motor problems, vision loss, seizures, and cognitive decline, culminating in premature death. Currently, no form of the disease can be treated or cured, with only palliative care to minimise discomfort. This review focuses on current and potentially ground-breaking clinical trials, including small molecule, enzyme replacement, stem cell, and gene therapies, in the development of effective treatments for the various disease subtypes. This article is part of a Special Issue entitled: "Current Research on the Neuronal Ceroid Lipofuscinoses (Batten Disease)".
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Batten disease; Cell therapy; Enzyme replacement therapy; Gene therapy; Neuronal ceroid lipofuscinosis; Small molecule therapy

Year:  2015        PMID: 25957554     DOI: 10.1016/j.bbadis.2015.04.026

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  13 in total

1.  A CLN6-CLN8 complex recruits lysosomal enzymes at the ER for Golgi transfer.

Authors:  Lakshya Bajaj; Jaiprakash Sharma; Alberto di Ronza; Pengcheng Zhang; Aiden Eblimit; Rituraj Pal; Dany Roman; John R Collette; Clarissa Booth; Kevin T Chang; Richard N Sifers; Sung Y Jung; Jill M Weimer; Rui Chen; Randy W Schekman; Marco Sardiello
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

Review 2.  Genetics of the neuronal ceroid lipofuscinoses (Batten disease).

Authors:  Sara E Mole; Susan L Cotman
Journal:  Biochim Biophys Acta       Date:  2015-05-27

3.  Longitudinal In Vivo Monitoring of the CNS Demonstrates the Efficacy of Gene Therapy in a Sheep Model of CLN5 Batten Disease.

Authors:  Nadia L Mitchell; Katharina N Russell; Martin P Wellby; Hollie E Wicky; Lucia Schoderboeck; Graham K Barrell; Tracy R Melzer; Steven J Gray; Stephanie M Hughes; David N Palmer
Journal:  Mol Ther       Date:  2018-07-17       Impact factor: 11.454

4.  Early infantile neuronal ceroid lipofuscinosis (CLN10 disease) associated with a novel mutation in CTSD.

Authors:  Stefano Doccini; Stefano Sartori; Stefan Maeser; Francesco Pezzini; Sara Rossato; Francesca Moro; Irene Toldo; Michael Przybylski; Filippo M Santorelli; Alessandro Simonati
Journal:  J Neurol       Date:  2016-04-12       Impact factor: 4.849

5.  Advances in the Treatment of Neuronal Ceroid Lipofuscinosis.

Authors:  Jonathan B Rosenberg; Alvin Chen; Stephen M Kaminsky; Ronald G Crystal; Dolan Sondhi
Journal:  Expert Opin Orphan Drugs       Date:  2019-11-27       Impact factor: 0.694

6.  Neurodegeneration and Epilepsy in a Zebrafish Model of CLN3 Disease (Batten Disease).

Authors:  Kim Wager; Anselm A Zdebik; Sonia Fu; Jonathan D Cooper; Robert J Harvey; Claire Russell
Journal:  PLoS One       Date:  2016-06-21       Impact factor: 3.240

Review 7.  Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders.

Authors:  Kyeongsoon Kim; Hynda K Kleinman; Hahn-Jun Lee; Kalipada Pahan
Journal:  Orphanet J Rare Dis       Date:  2017-06-17       Impact factor: 4.123

Review 8.  An Overview of the Role of Lipofuscin in Age-Related Neurodegeneration.

Authors:  Alexandra Moreno-García; Alejandra Kun; Olga Calero; Miguel Medina; Miguel Calero
Journal:  Front Neurosci       Date:  2018-07-05       Impact factor: 4.677

9.  Detection of Infantile Batten Disease by Tandem Mass Spectrometry Assay of PPT1 Enzyme Activity in Dried Blood Spots.

Authors:  Hamid Khaledi; Yang Liu; Sophia Masi; Michael H Gelb
Journal:  Anal Chem       Date:  2018-09-24       Impact factor: 8.008

10.  A tailored mouse model of CLN2 disease: A nonsense mutant for testing personalized therapies.

Authors:  Ryan D Geraets; Logan M Langin; Jacob T Cain; Camille M Parker; Rosanna Beraldi; Attila D Kovacs; Jill M Weimer; David A Pearce
Journal:  PLoS One       Date:  2017-05-02       Impact factor: 3.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.